ATAI Life Sciences NV (NAS:ATAI)
$ 1.35 0.17 (14.41%) Market Cap: 226.53 Mil Enterprise Value: 129.29 Mil PE Ratio: 0 PB Ratio: 1.18 GF Score: 44/100

ATAI Life Sciences NV at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 11, 2021 / 02:40PM GMT
Release Date Price: $14.57 (-1.89%)
Judah C. Frommer;dit Suisse AG
CrÃ;Research Division - Senior Analyst

© -

Hi, everyone, and welcome to day 4 of the 2021 Credit Suisse Healthcare Conference. I'm Judah Frommer. I cover biotech here at CS. And we're thrilled to have a tie with us. There's been some news in the space that we'll get into. But first, let me introduce Florian Brand, CEO; Srinivas Rao, Chief Scientific Officer; and Chad Mester, who recently joined as Head of IR. Thanks, again for your participation, everyone. And I figure we could just jump right into Q&A before we get to the news of the week. Maybe you could just first, talk about the data platform. And maybe a good place to start is just the level of unmet need in neurocyte and mental health and what the impetus was for creating the platform.

Questions & Answers

Florian Brand
Atai Life Sciences N.V. - Co-Founder, MD & CEO

Sure. I'm happy to. Thanks for inviting us over to a little bit on our story and also the founding story that you mentioned because our -- I think it's important to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot